| Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. Co. is conducting HOPE-2, a Phase II clinical trial in the United States with its product candidate, CAP-1002, a cardiac cell derived therapy which is being used to treat patients with late-stage DMD. Additionally, Co. is developing its exosomes platform technology as a vaccine and therapeutic investigating a variety of disorders. Exosomes act as messengers to regulate the functions of neighboring or distant cells. We show 33 historical shares outstanding datapoints in our coverage of CAPR's shares outstanding history.|
Understanding the changing numbers of CAPR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CAPR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CAPR by allowing them to research CAPR shares outstanding history
as well as any other stock in our coverage universe.